Current perspectives on glycopeptide resistance

Clinical Microbiology Reviews

Volumn 8, Issue 4, 1995, Pages 585-615

  Woodford, Neil ^a   Johnson, Alan P ^a   Morrison, Donald ^a   Speller, David C E ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; BACTERIAL INFECTION; ENTEROCOCCUS; GEOGRAPHIC DISTRIBUTION; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; LACTIC ACID BACTERIUM; NONHUMAN; PHENOTYPE; REVIEW; STAPHYLOCOCCUS;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; POSIBACTERIA; STAPHYLOCOCCUS;

EID: 0028889418     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.8.4.585     Document Type: Review

References (429)

1. Acar, J. F., and A. Y. Buu-Hoi. 1988. Resistance patterns of important gram-positive pathogens. J. Antimicrob. Chemother. 21(Suppl. C):41-47.
2. Aldridge, K. E. 1992. In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents. Antimicrob. Agents Chemother. 36:851-853.
3. Aldridge, K. E., D. D. Schiro, and L. M. Varner. 1992. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob. Agents Chemother. 36:854-855.
4. Allen, N. E., J. N. Hobbs, Jr., J. M. Richardson, and R. M. Riggin. 1992. Biosynthesis of modified peptidoglycan precursors by vancomycin-resistant Enterococcus faecium. FEMS Microbiol. Lett. 98:109-115.
5. al-Obeid, S., D. Billot-Klein, J. van Heijenoort, E. Collatz, and L. Gutmann, 1992. Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin-β-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366. FEMS Microbiol. Lett. 91:79-84.
6. al-Obeid, S., E. Collatz, and L. Gutmann. 1990. Mechanism of resistance to vancomycin in Enterococcus faecium D366 and Enterococcus faecalis A256. Antimicrob. Agents Chemother. 34:252-256.
7. al-Obeid, S., L. Gutmann, D. M. Shlaes, R. Williamson, and E. Collatz. 1990. Comparison of vancomycin-inducible proteins from four strains of Enterococci. FEMS Microbiol. Lett. 70:101-106.
8. Amsterdam, D., E. A. Gorzynski, T. R. Beam, and C. Holstein. 1994. Susceptibility of bacteremic isolates of gram-positive cocci to daptomycin and other antimicrobial agents. J. Antimicrob. Chemother. 33:1060-1064.
9. Anonymous. 1993. Vancomycin resistance in enterococci. Communicable Dis. Rep. Weekly 4(9).
10. Anonymous. 1993. Nosocomial enterococci resistant to vancomycin - United States. Morbid. Mortal. Weekly Rep. 42:597-599.
11. Archer, G. L., and M. W. Climo. 1994. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob. Agents Chemother. 38: 2231-2237.
12. Arthur, M., and P. Courvalin. 1993. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37:1563-1571.
13. Arthur, M., F. Depardieu, C. Molinas, P. Reynolds, and P. Courvalin. 1995. The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin. Gene 154:87-92.
14. Arthur, M., F. Depardieu, H. A. Snaith, P. E. Reynolds, and P. Courvalin. 1994. Contribution of Van Y D,D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob. Agents Chemother. 38:1899-1903.
15. Arthur, M., C. Molinas, T. D. H. Bugg, G. D. Wright, C. T. Walsh, and P. Courvalin. 1992. Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 36:867-869.
16. Arthur, M., C. Molinas, and P. Courvalin. 1992. The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 174:2582-2591.
17. Arthur, M., C. Molinas, and P. Courvalin. 1992. Sequence of the vanY gene required for production of a vancomycin-inducible D,D-carboxypeptidase in Enterococcus faecium BM4147. Gene 120:111-114.
18. Arthur, M., C. Molinas, F. Depardieu, and P. Courvalin. 1993. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 175:117-127.
19. Arthur, M., C. Molinas, S. Dutka-Malen, and P. Courvalin. 1991. Structural relationship between the vancomycin resistance protein VanH and 2-hydroxycarboxylic acid dehydrogenases. Gene 103:133-134.
20. Atkins, M. C., L. Nicolson, G. A. J. Harrison, A. Paull, H. Malnick, and D. Morrison. 1990. Lactobacillus jensenii prosthetic valve endocarditis. J. Hosp. Infect. 21:322-324.
21. Aubert, G., S. Passot, F. Lucht, and G. Dorche. 1990. Selection of vancomycin- and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of Staphylococcus epidermidis infection. J. Antimicrob. Chemother. 25:491-493.
22. Aukenthaler, R., W. R. Wilson, A. J. Wright, J. A. Washington, D. T. Durack, and J. E. Geraci. 1982. Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci. Antimicrob. Agents Chemother. 22:448-452.
23. Baillie, L. W. J., J. J. Wade, and M. W. Casewell. 1992. Chlorhexidine sensitivity of Enterococcus faecium resistant to vancomycin, high levels of gentamicin. or both. J. Hosp. Infect. 20:127-128. (Letter.)
24. Baker, C. N., S. A. Stocker, D. H. Culver, and C. Thornsberry. 1991. Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J. Clin. Microbiol. 29:533-538.
25. Ball, P. 1990. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic strategies. J. Antimicrob. Chemother. 26(Suppl. F):165-179.
26. Bannerman, T. L., D. L. Wadiak, and W. E. Kloos. 1991. Susceptibility of Staphy/ococcus species and subspecies to teicoplanin. Antimicrob. Agents Chemother. 35:1919-1922.
27. Bantar, C. E., S. Relloso, F. R. Castell, J. Smayevsky, and H. M. Bianchini. 1991. Abscess caused by vancomycin-resistant Lactobacillus confusus. J. Clin. Microbiol. 29:2063-2064.
28. Barnass, S., K. Holland, and S. Tabaqchali. 1991. Vancomycin-resistant Cotynebacterium species causing prosthetic endocarditis successfully treated with imipenem and ciprofloxacin. J. Infect. 22:161-169.
29. Barreau, C., and G. Wagener. 1990. Characterization of Leuconostoc lactis strains from human sources. J. Clin. Microbiol. 28:1728-1733.
30. Barrett, M. S., R. P. Wenzel, and R. N. Jones. 1992. In vitro activity of mersacidin (M87-1551), an investigational antibiotic tested against gram-positive bloodstream isolates. Diagn. Microbiol. Infect. Dis. 15:641-644.
31. Barry, A. L., and P. C. Fuchs. 1991. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob. Agents Chemother. 35:955-960.
32. Barry, A. L., and R. N. Jones. 1989. In-vitro activities of temofloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J. Antimicrob. Chemother. 23:527-535.
33. Barry, A. L., R. N. Jones, T. L. Gavan, C. Thornsberry, and the Collaborative Antimicrobial Susceptibility Testing Group. 1987. Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria. J. Clin. Microbiol. 25:1812-1814.
34. Bartoloni, A., M. G. Colao, A. Orsi, R. Dei, E. Giganti, and F. Parenti. 1990. In-vitro activity of vancomycin, teicoplanin, daptomycin, MDL 62873 and other agents against staphylococci, enterococci and Chostridium difficile. J. Antimicrob. Chemother. 26:627-633.
35. Bates, J., J. Z. Jordens, and D. T. Griffiths. 1994. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J. Antimicrob. Chemother. 34:507-514.
36. Bauernfeind, A. 1992. Bactericidal activity of antibiotics alone and in combination against Enterococcus faecalis in a pharmacodynamic model. Clin. Infect. Dis. 15:481-485.
37. Bayer, A. S., A. W. Chow, D. Betts, and L. B. Guze. 1978. Lactobacillemia - report of nine cases. Important clinical and therapeutic considerations. Am. J. Med. 64:808-813.
38. Bayer, A. S., A. W. Chow, J. O. Morrison, and L. B. Guze. 1980. Bactericidal synergy between penicillin or ampicillin and aminoglycosides against antibiotic-tolerant lactobacilli. Antimicrob. Agents Chemother. 17:359-363.
39. Benson, C. A., F. Beaudette, and G. Trenholm. 1987. Comparative in-vitro activity of LY 146032, a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J. Antimicrob. Chemother. 20:191-196.
40. Bernaldo de Quiros, J. C. L., P. Munoz, E. Cercenado, T. Hernandez Sampelayo, S. Moreno, and E. Bouza. 1991. Leuconostoc species as a cause of bacteremia: two case reports and a literature review. Eur. J. Clin. Microbiol. Infect. Dis. 10:505-509.
41. Biavasco, F., E. Giovanetti, M. P. Montanari, R. Lupidi, and P. E. Varaldo. 1991. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J. Antimicrob. Chemother. 27: 71-79.
42. Biavasco, F., R. Lupidi, and P. E. Varaldo. 1992. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873. Antimicrob. Agents Chemother. 36:331-338.
43. Biavasco, F., E. Manso, and P. E. Veraldo. 1991. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 35:195-197.
44. Billot-Klein, D., L. Gutmann, E. Collatz, and J. van Heijenoort. 1992. Analysis of peptidoglycan precursors in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 36:1487-1490.
45. Billot-Klein, D., L. Gutmann, S. Sable, E. Guittet, and J. van Heijenoort. 1994. Modification of peptidoglyean precursors is a common feature of the low-level vancomycin-resistant VANB-type Enlerococcus D366 and of the naturally glycopeptide-resistant species Laclobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J. Bacteriol. 176:2398-2405.
46. Bingen, E., C. Doit, N. Lambert-Zechovsky, M. Tod, O. Petitjean, F. Bourgeois, and P. Mariani-Kurkdjian. 1991. Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model. Eur. J. Clin. Microbiol. Infect. Dis. 10:1062-1065.
47. Bingen, E., N. Lambert-Zechovsky, R. Leclercq, C. Doit, and P. Mariani-Kurkdjian. 1990. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enteroccus faecium. J. Antimicrob. Chemother. 26:619-626.
48. Bingen, E. H., E. Denamur, N. Y. Lambert-Zechovsky, and J. Elion. 1991. Evidence for the genetic unrelatedness of nosocomial vancomycin-resistant Enterococcus faecium strains in a pediatric hospital. J. Clin. Microbiol. 29:1888-1892.
49. Bisno, A. L., W. E. Dismukes, D. T. Durack, E. L. Kaplan, A. W. Karchmer, D. Kaye, S. H. Rahimtoola, M. A. Sande, J. P. Sanford, C. Watanakunakorn, and W. R. Wilson. 1989. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci and staphylococci. JAMA 261:1471-1477.
50. Boiron, P., F. Provost, G. Chevrier, and B. Dupont. 1992. Review of nocardial infections in France 1987 to 1990. Eur. J. Clin. Microbiol. Infect. Dis. 11:709-714.
51. Bolstrom, A., and A. Karlsson. 1992. Susceptibility testing of glycopeptides with a predefined antibiotic gradient, abstr. 1619. In Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
52. Boyce, J. M., S. M. Opal, J. W. Chow, M. J. Zervos, G. Potter-Bynoe, C. B. Sherman, R. L. C. Romulo, S. Fortna, and A. A. Medeiros. 1994. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J. Clin. Microbiol. 32:1148-1153.
53. Boyle, J. F., S. A. Soumakis, A. Rendo, J. A. Herrington, D. G. Gianarkis, B. E. Thurberg, and B. G. Painter. 1993. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J. Clin. Microbiol. 31:1280-1285.
54. Brisson-Noel, A., S. Dutka-Malen, C. Molinas, R. Leclercq, and P. Courvalin. 1990. Cloning and heterospecific expression of the resistance determinant vanA encoding high-level resistance to glycopeptides in Enterococcus faecium BM4147. Antimicrob. Agents Chemother. 34:924-927.
55. Brown, D. F. J., and L. Brown. 1991. Evaluation of the E test, a novel method of quantifying antimicrobial activity. J. Antimicrob. Chemother. 27:185-190.
56. Brown, E. M., P. M. Hawkey, D. C. E. Speller, and P. J. Daly (ed.). 1990. Ciprofloxacin - defining its role today. J. Antimicrob. Chemother. 26 (Suppl. F):31.
57. Brunet, F., G. Vedel, F. Dreyfus, J. F. Vaxelaire, T. Giraud, B. Schremmer, and J. F. Monsallier. 1994. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 9:145-147.
58. Bugg, T. D. H., S. Dutka-Malen, M. Arthur, P. Courvalin, and C. T. Walsh. 1991. Identification of vancomycin resistance protein VanA as a D-alanine: D-alanine ligase of altered substrate specificity. Biochemistry 30:2017-2021.
59. Bugg, T. D. H., G. D. Wright, S. Dutka-Malen, M. Arthur, P. Courvalin, and C. T. Walsh. 1991. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30:10408-10415.
60. Burney, S., D. Landman, and J. Quale. 1994. Ramoplanin and penicillin therapy of experimental endocarditis due to multidrug-resistant Enterococcus faecium, abstr. B71. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
61. Burney, S., D. Landman, and J. M. Quale. 1994. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:1668-1670.
62. Buschelman, B. J., and R. N. Jones. 1993. Newer glycopeptide antibiotics tested against nosocomial bloodstream isolates. J. Antimicrob. Chemother. 31:445-447.
63. Bush, L. M., J. A. Boscia, and D. Kaye. 1988. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 32:877-881.
64. Calain, P., K.-H. Krause, P. Vaudaux, R. Aukenthaler, D. Lew, F. Waldvogel, and B. Hirschel, 1987. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J. Infect. Dis. 155:187-191.
65. Caron, F., C. Carbon, and L. Gutmann. 1991. Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium. J. Infect. Dis. 164:888-893.
66. Caron, F., M.-D. Kitzis, L. Gutmann, A.-C. Cremieux, B. Maziere, J. M. Vallois, A. Saleh-Mghir, J.-F. Lemeland, and C. Carbon. 1992. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob. Agents Chemother. 36:2611-2616.
67. Caron, F., J. F. Lemeland, G. Humbert, I. Klare, and L. Gutmann. 1993. Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin- and glycopeptide-resistant isolate of Enterococcus faecium. J. Infect. Dis. 168:681-686.
68. Carpenter, T. C., C. J. Hackbarth, H. F. Chambers, and M. A. Sande. 1986. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 30:382-384.
69. Cavenaghi, L. A., E. Biganzoli, A. Danese, and F. Parenti. 1992. Diffusion of teicoplanin and vancomycin in agar. Diagn. Microbiol. Infect. Dis. 15: 253-258.
70. Cercenado, E., G. M. Eliopoulos, S. Unal, C. B. Wennersten, M. Rodriguez-Creixems, and R. C. Moellering, Jr. 1992. Characterization of vancomycin-resistant enterococci from a Spanish hospital, abstr. 1172. In Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
71. Cercenado, E., G. M. Eliopoulos, C. B. Wennersten, and R. C. Moellering, Jr. 1992. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 36:2201-2203.
72. Cercenado, E., M. E. Garcia-Leoni, J. C. L. Bernaldo de Quiros, M. D. Diaz, P. Catalan, and E. Bouza. 1993. Emergence of teicoplanin-resistant coagulase-negative staphylococci, abstr. 1041, p. 310. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
73. Chadwick, P., and B. A. Oppenheim. 1994. Vancomycin-resistant enterococci and bedpan washer machines. Lancet 344:685.
74. Chambers, H. F. 1993. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect. Dis. Clin. N. Am. 7:69-80.
75. Cheesbrough, J. S., S. R. Smith, and J. M. Davies. 1990. The potential impact on clinical practice of differences in the in vitro activity of vancomycin and teicoplanin. J. Antimicrob. Chemother. 25:716-718.
76. Chenoweth, C. E., K. A. Robinson, and D. R. Schaberg. 1990. Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis. Antimicrob. Agents Chemother. 34:1800-1802.
77. Chin, N.-X., and H. C. Neu. 1991. In vitro activity of LY264826 compared to other glycopeptides and daptomycin. Diagn. Microbiol. Infect. Dis. 14: 181-184.
78. Chomarat, M., and D. Espinouse. 1991. Lactobacillus rhamnosus septicemia in patients with prolonged aplasia receiving ceftazidime-vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 10:44.
79. Chomarat, M., D. Espinouse, and J.-P. Flandrois. 1991. Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity. J. Antimicrob. Chemother. 27:475-480.
80. Chow, J. W., A. Kuritza, D. M. Shlaes, M. Green, D. F. Sahm, and M. J. Zervos. 1993. Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J. Clin. Microbiol. 31: 1609-1611.
81. Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover. 1993. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37:2311-2317.
82. Clark, N. C., B. C. Hill, and F. C. Tenover. 1994. Characterization of an Enterococcus raffinosus isolate with a VanB phenotype and vanA genotype, abstr. A-111. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.
83. Cohen, M. A., M. D. Huband, G. B. Mailloux, S. L. Yoder, G. E. Roland, J. M. Domagala, and C. L. Heifetz. 1991. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob. Agents Chemother. 35:141-146.
84. Collins, L. A., G. M. Eliopoulos, C. B. Wennersten, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob. Agents Chemother. 37: 1364-1366.
85. Collins, L. A., G. J. Malanoski, G. M. Eliopoulos, C. B. Wennersten, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob. Agents Chemother. 37:598-601.
86. Corcoran, G. D., N. Gibbons, and T. E. Mulvihill. 1991. Septicaemia caused by Pediococcus pentosaceus: a new opportunistic pathogen. J. Infect. 23: 179-182.
87. Daum, R. S., S. Gupta, R. Sabbagh, and W. M. Milewski. 1992. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J. Infect. Dis. 166:1066-1072.
88. Davies, A. J., P. A. James, and P. M. Hawkey. 1986. Lactobacillus endocarditis. J. Infect. 12:169-174.
89. Dean, J., E. Venuti, and H. Fraimow. 1994. Vancomycin-resistant enterococci of the vanB genotype demonstrating glycopeptide resistance inducible by vancomycin or teicoplanin, abstr. A-109. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994, American Society for Microbiology, Washington, D.C.
90. de la Maza, L., K. L. Ruoff, and M. J. Ferraro. 1989. In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria. Antimicrob. Agents Chemother. 33:1383-1384.
91. Dembry, L. M., L. Saravolatz, M. Somero, A. P. Durbin, S. Miller, and M. J. Zervos. 1994. Clonal spread of a unique vancomycin-resistant phenotype of Enterococcus faecium between patients in four hospitals in southeastern Michigan, abstr. L-13. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994, American Society for Microbiology, Washington, D.C.
92. Devriese, L. A., B. Pot, and M. D. Collins. 1994. Phenotypic identification of the genus Enterococcus and differentiation of phylogenetically distinct enterococcal species and species groups. J. Appl. Bacteriol. 75:399-408.
93. Donabedian, S. M., J. W. Chow, J. M. Boyce, R. E. McCabe, S. M. Markowitz, P. E. Coudron, A. Kuritza, C. L. Pierson, and M. J. Zervos. 1992. Molecular typing of ampicillin-resistant, non-β-lactamase-producing Enterococcus faecium isolates from diverse geographic areas. J. Clin. Microbiol. 30:2757-2761.
94. Dong, M.-Y., T.-W. Chang, and S. L. Gorbach. 1987. Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032. Antimicrob. Agents Chemother. 31:1135-1136.
95. Dutka-Malen, S., B. Blaimont, G. Wauters, and P. Courvalin. 1994. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob. Agents Chemother. 38:1675-1677.
96. Dutka-Malen, S., and P. Courvalin. 1994. Résistance aux glycopeptides et aux aminosides chez les entérocoques. Med. Mal. Infect. 24(Special):158-164.
97. Dutka-Malen, S., S. Evers, and P. Courvalin. 1995. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:24-27. (Erratum 33: 1434, 1995.)
98. Dutka-Malen, S., R. Leclercq, V. Coutant, J. Duval, and P. Courvalin. 1990. Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria. Antimicrob. Agents Chemother. 34: 1875-1879.
99. Dutka-Malen, S., C. Molinas, M. Arthur, and P. Courvalin. 1990. The VANA glycopeptide resistance protein is related to D-alanyl-D-alanine ligase cell wall biosynthesis enzymes. Mol. Gen. Genet. 224:364-372.
100. Dutka-Malen, S., C. Molinas, M. Arthur, and P. Courvalin. 1992. Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine: D-alanine ligase-related protein necessary for vancomycin resistance. Gene 112:53-58.
101. Dworkin, R. J., B. L. Lee, M. A. Sande, and H. F. Chambers. 1989. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet ii:1071-1073.
102. Edberg, S. C., C. J. Hardalo, C. Kontnick, and S. Campbell. 1994. Rapid detection of vancomycin-resistant enterococci. J. Clin. Microbiol. 32:2182-2184.
103. Eliopoulos, G. M. 1993. Aminoglycoside resistant enterococcal endocarditis. Infect. Dis. Clin. N. Am. 7:117-133.
104. Eliopoulos, G. M., and C. T. Eliopoulos. 1990. Therapy of enterococcal infections. Eur. J. Clin. Microbiol. Infect. Dis. 9:118-126.
105. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
106. Eliopoulos, G. M., C. Thauvin-Eliopoulos, and R. C. Moellering, Jr. 1992. Contribution of animal models in the search for effective therapy for endocarditis due to enterococci with high-level resistance to gentamicin. Clin. Infect. Dis. 15:58-62.
107. Eliopoulos, G. M., C. B. Wennersten, G. Cole, and R. C. Moellering. 1994. In vitro activity of two glycylcyclines against gram-positive bacteria. Antimicrob. Agents Chemother. 38:534-541.
108. Eliopoulos, G. M., S. Willey, B. E. Murray, and R. C. Moellering, Jr. 1989. Ciprofloxacin in experimental endocarditis due to a β-lactamase-producing, highly gentamicin-resistant strain of Enterococcus faecalis. Rev. Infect. Dis. 11(Suppl. 5):S1210-1211.
109. Elisha, B. G., and P. Courvalin. 1995. Analysis of genes encoding D-alanine: D-alanine ligase-related enzymes in Leuconostoc mesenteroides and Lactobacillus spp. Gene 152:79-83.
110. el-Mady, A., and J. E. Mortensen. 1991. The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant Enterococcus faecium. Diagn. Microbiol. Infect. Dis. 14:141-145.
111. Entenza, J. M., T. Calandra, Y. Moosmann, R. Malinverni, and M. P. Glauser. 1992. Teicoplanin versus vancomycin for prophylaxis of experimental Enterococcus faecalis endocarditis in rats. Antimicrob. Agents Chemother. 36:1256-1262.
112. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1994. RP 59500 (quinupristin-dalfopristin) treatment of experimental endocarditis due to erythromycin-sensitive and -resistant strains of methicillin-resistant Staphylococcus aureus, abstr. B77. Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
113. Etienne, S. D., G. Montay, A. Le Liboux, A. Frydman, and J. J. Garaud. 1992. A phase I, double blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J. Antimicrob. Chemother. 30 (Suppl. A):123-131.
114. Evers, S., P. E. Reynolds, and P. Courvalin. 1994. Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine:D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583. Gene 140:97-102.
115. Evers, S., D. F. Sahm, and P. Courvalin. 1993. The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding D-Ala:D-Ala ligases and glycopeptide-resistance proteins VanA and VanC. Gene 124:143-144.
116. Fantin, B., R. Leclercq, M. Arthur, J. Duval, and C. Carbon. 1991. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob. Agents Chemother. 35:1570-1575.
117. Fantin, B., R. Leclercq, Y. Merle, L. Saint-Julien, C. Veyrat, J. Duval, and C. Carbon. 1995. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. 39:400-405.
118. Fass, R. J. 1991. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. 35:553-559.
119. Felmingham, D. 1993. Towards the ideal glycopeptide. J. Antimicrob. Chemother. 32:663-666.
120. Felmingham, D., K. Solomonides, M. D. O'Hare, A. P. R. Wilson, and R. N. Gruneberg. 1987. The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci. J. Antimicrob. Chemother. 20:609-610.
121. Fernandez-Guerrero, M., M. S. Rouse, N. K. Henry, J. E. Geraci, and W. R. Wilson. 1987. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob. Agents Chemother. 31:430-433.
122. Fowler, C., G. Scully, M. Willy, V. Gill, and H. Standiford. 1991. Vancomycin-resistant enterococci: successful treatment of infection in two lymphoma patients using teicoplanin, abstr. A-58. In Abstracts of the 91st General Meeting of the American Society for Microbiology 1994, American Society for Microbiology, Washington, D.C.
123. Fraimow, H. S. (University of Pennsylvania). 1994. Personal communication.
124. Fraimow, H. S., D. L. Jungkind, D. W. Lander, D. R. Delso, and J. L. Dean. 1994. Urinary tract infection with an Enterococcus faecalis isolate that requires vancomycin for growth. Ann. Intern. Med. 121:22-26.
125. Fraimow, H. S., and E. Venuti. 1992. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 36:1563-1566.
126. Fraimow, H., E. Venuti, and J. Dean. 1993. Mechanism of vancomycin dependence of a vancomycin-requiring clinical Enterococcus faecalis isolate, abstr. 117. In Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
127. Francis, J., H. Webster, and S. W. B. Newsom. 1990. In vitro activity of ramoplanin on staphylococci. Drugs Exp. Clin. Res. 16:457-460.
128. Frankel, D. H. 1994. Resistant enterococci in California. Lancet 343:1560.
129. Freeman, R., A. M. Kearns, and N. F. Lightfoot. 1994. Heat resistance of nosocomial enterococci. Lancet 344:63-64.
130. French, G., Y. Abdulla, R. Heathcock, S. Poston, and J. Cameron. 1992. Vancomycin resistance in south London. Lancet 339:818-819.
131. French, P., E. Venuti, and H. S. Fraimow. 1993. In vitro activity of novobiocin against multidrug-resistant strains of Enterococcus faecium. Antimicrob. Agents Chemother. 37:2736-2739.
132. Frieden, T. R., S. S. Munsiff, D. E. Low, B. M. Willey, G. Williams, Y. Faur, W. Eisner, S. Warren, and B. Kreiswirth. 1993. Emergence of vancomycin-resistant enterococci in New York City. Lancet 342:76-79.
133. Friedland, I. R., M. Snipelisky, and M. Khoosal. 1990. Meningitis in a neonate caused by Leuconostoc sp. J. Clin. Microbiol. 28:2125-2126.
134. Funke, G., A. von Graevenitz, and N. Weiss. 1994. Primary identification of Aureobacterium spp. isolated from clinical specimens as "Corynebacterium aquaticum." J. Clin. Microbiol. 32:2686-2691.
135. Furlong, W. B., and F. Bompart. 1994. Therapy for enterococci with VanA/ VanB resistance patterns using RP 59500 (quinupristin-dalfopristin), abstr. M66. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
136. Galanakis, N., H. Giamarellou, N. Vlachogiannis, C. Dendrinos, and G. K. Daikos. 1988. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. Eur. J. Clin. Microbiol. Infect. Dis. 7:130-134.
137. Garrison, M. W., J. C. Rotschafer, and K. B. Crossley. 1989. Suboptimal effects of daptomycin in the treatment of bacteremias. South. Med. J. 82:1414-1415.
138. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rotschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcua aureus by using an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 34:1925-1931.
139. Geraci, J. E., and W. J. Martin. 1954. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis: clinical, pathologic, and therapeutic consideration of 33 cases. Circulation 10:173-194.
140. Gold, H. S., S. Unal, E. Cercenado, C. Thauvin-Eliopoulos, G. M. Eliopoulos, and R. C. Moellering, Jr. 1993. A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob. Agents Chemother. 37:1604-1609.
141. Gold, M. J., J. Calmon, M. Wendeler, M. E. Levison, and C. C. Johnson. 1991. Synergistic bactericidal activity of rat serum with vancomycin against enterococci. J. Infect. Dis. 163:1358-1361.
142. Goldstein, F. W., A. Coutrot, A. Sieffer, and J. F. Acar. 1990. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob. Agents Chemother. 34:899-900.
143. Golledge, C. L. 1991. Infection due to Leuconostoc species. Rev. Infect. Dis. 13:184-185.
144. Golledge, C. L., N. Stingemore, M. Aravena, and D. Joske. 1990. Septicemia caused by vancomycin-resistant Pediococcus acidilactici. J. Clin. Microbiol. 28:1678-1679.
145. Gorby, G. L., and J. E. Peacock, Jr. 1988. Erysipelothrix rhusiopathiae endocarditis: microbiologic, epidemiologic and clinical features of an occupational disease. Rev. Infect. Dis. 10:317-325.
146. Gordillo, M. E., K. V. Singh, and B. E. Murray. 1993. Comparison of ribotyping and pulsed-field gel electrophoresis for subspecies differentiation of strains of Enterococcus faecalis. J. Clin. Microbiol. 31:1570-1574.
147. Gordon, S., J. M. Swenson, B. C. Hill, N. E. Pigott, R. R. Facklam, R. C. Cooksey, C. Thornsberry, Enterococcal Study Group, W. R. Jarvis, and F. C. Tenover. 1992. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. J. Clin. Microbiol. 30:2373-2378.
148. Goto, S., S. Miyasaki, and Y. Kaneko. 1992. The in-vitro activity of RP 59500 against gram-positive cocci. J. Antimicrob. Chemother. 30(Suppl. A): 25-28.
149. Gradon, J. 1994. Unexpected rectal carriage of an aminoglycoside- and vancomycin-resistant Enterococcus faecium. Clin. Microbiol. Newsl. 16:79-80.
150. Graninger, W., and R. Ragette. 1992. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin. Infect. Dis. 15:49-57.
151. Gransden, W. R., and S. J. Eykyn. 1988. Erysipelothrix rhusiopathiae endocarditis. J. Infect. Dis. 10:1228.
152. Gray, J., P. J. Marsh, D. Stewart, and S. J. Pedler. 1994. Enterococcal bacteraemia: a prospective study of 125 episodes. J. Hosp. Infect. 27:179-186.
153. Gray, J. W., and S. J. Pedler. 1992. Antibiotic-resistant enterococci. J. Hosp. Infect. 21:1-14.
154. Gray, J. W., S. J. Pedler, J. Kernahan, A. D. J. Pearson, and A. W. Craft. 1992. Enterococcal superinfection in paediatric oncology patients treated with imipenem. Lancet i:1487-1488.
155. Grayson, M. L., C. Thauvin-Eliopoulos, G. M. Eliopoulos, J. D. C. Yao, D. V. DeAngelis, L. Walton, J. L. Woolley, and R. C. Moellering, Jr. 1990. Failure of trimethoprim-sulphamethoxazole in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 34:1792-1794.
156. Green, M., K. Barbadora, and M. Michaels. 1991. Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients. J. Clin. Microbiol. 29:2503-2506.
157. Green, M., B. Binczewski, A. W. Pasculle, M. Edmund, K. Barbadora, S. Kusne, and D. M. Shlaes. 1993. Constitutively vancomycin-resistant Enterococcus faecium resistant to synergistic β-lactam combinations. Antimicrob. Agents Chemother. 37:1238-1242.
158. Green, M., J. H. Shlaes, K. Barbadora, and D. M. Shlaes. 1995. Bacteremia due to vancomycin-dependent Enterococcus faecium. Clin. Infect. Dis. 20: 712-714.
159. Green, M., R. M. Wadowsky, and K. Barbadora. 1990. Recovery of vancomycin-resistant gram-positive cocci from children. J. Clin. Microbiol. 28: 484-488.
160. Greenberg, R. N., and C. A. Benes. 1990. Time-kill studies with oxacillin, vancomycin, and teicoplanin versus Staphylococcus aureus. J. Infect. Dis. 161:1036-1037.
161. Griffith, R. S. 1984. Vancomycin use - an historical review. J. Antimicrob. Chemother. 14(Suppl. D):1-5.
162. Griffiths, J. K., J. S. Daly, and R. A. Dodge. 1992. Two cases of endocarditis due to Lactobacillus species: antimicrobial susceptibility, review and discussion of therapy. Clin. Infect. Dis. 15:250-255.
163. Gringas, B. A., P. Coudron, D. Williams, S. Markowitz, and H. P. Dalton. 1994. An outbreak of vancomycin-resistant Enterococcus faecium in a tertiary care hospital, abstr. L-38. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994, American Society for Microbiology, Washington. D.C.
164. Guiot, H. F., W. E. Peetermans, and F. W. Sebens. 1991. Isolation of vancomycin-resistant enterococci in haematologic patients. Eur. J. Clin. Microbiol. Infect. Dis. 10:32-34.
165. Gullberg, R. M., S. R. Homann, and J. P. Phair. 1989. Enterococcal bacteremia: analysis of 75 episodes. Rev. Infect. Dis. 11:74-85.
166. Gutmann, L., S. al-Obeid, D. Billot-Klein, M.-L. Guerrier, and E. Collatz. 1994. Synergy and resistance to synergy between β-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium. Antimicrob. Agents Chemother. 38:824-829.
167. Gutmann, L., D. Billot-Klein, S. al-Obeid, I. Klare, S. Francoual, E. Collatz, and J. van Heijenoort. 1992. Inducible carboxypeptidase activity in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 36:77-80.
168. Gutmann, L., F. W. Goldstein, M. D. Kitzis, B. Hautefort, C. Darmon, and J. F. Acar. 1983. Susceptibility of Nocardia asteroides to 46 antibiotics including 22 β-lactams. Antimicrob. Agents Chemother. 23:248-251.
169. Gutschik, E. 1993. The enterococcus endocarditis model in experimental animals and its relevance to human infection. J. Antimicrob. Chemother. 31(Suppl. D):87-95.
170. Hall, L. M., H. Y. Chen, and R. J. Williams. 1992. Vancomycin-resistant Enterococcus durans. Lancet 340:1105.
171. Hall, L. M., B. Duke, M. Guiney, and R. Williams. 1992. Typing of Enterococcus species by DNA restriction fragment analysis. J. Clin. Microbiol. 30:915-919.
172. Hamilton-Miller, J. M. 1992. In vitro activity of fosfomycin against 'problem' gram-positive cocci. Microbios 71:95-103.
173. Hamilton-Miller, J. M. T., and D. Purves. 1986. Enterococci and antifolate antibiotics. Eur. J. Clin. Microbiol. 5:391-394.
174. Handwerger, S. 1994. Alterations in peptidoglycan precursors and vancomycin susceptibility in Tn917 insertion mutants of Enterococcus faecalis 221. Antimicrob. Agents Chemother. 38:473-475.
175. Handwerger, S., L. Discotto, J. Thanassi, and M. J. Pucci. 1992. Insertional inactivation of a gene which controls expression of vancomycin resistance on plasmid pHKK100. FEMS Microbiol. Lett. 92:11-14.
176. Handwerger, S., H. Horowitz, K. Coburn, A. Kolokathis, and G. P. Wormser. 1990. Infection due to Leuconostoc species: six cases and review. Rev. Infect. Dis. 12:602-610.
177. Handwerger, S., and A. Kolokathis. 1990. Induction of vancomycin resistance in Enterococcus faecium by inhibition of transglycosylation. FEMS Microbiol. Lett. 58:167-170.
178. Handwerger, S., D. C. Perlman, D. Altarac, and V. McAuliffe. 1992. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin. Infect. Dis. 14:655-661.
179. Handwerger, S., M. J. Pucci, K. J. Volk, J. Liu, and M. S. Lee. 1992. The cytoplasmic peptidoglycan precursor of vancomycin-resistant Enterococcus faecalis terminates in lactate. J. Bacteriol. 174:5982-5984.
180. Handwerger, S., M. J. Pucci, K. J. Volk, J. Liu, and M. S. Lee. 1994. Vancomycin-resistant Leuconostoc mesenteroides and Lactobacillus casei synthesize cytoplasmic peptidoglycan precursors that terminate in lactate. J. Bacteriol. 176:260-264.
181. Handwerger, S., B. Raucher, D. Altarac, J. Monka, S. Marchione, K. V. Singh, B. E. Murray, J. Wolff, and B. Walters. 1993. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin. Infect. Dis. 16:750-755.
182. Handwerger, S., J. Skoble, L. F. Discotto, and M. J. Pucci. 1995. Heterogeneity of the vanA gene cluster in clinical isolates of enterococci from the northeastern United States. Antimicrob. Agents Chemother. 39:362-368.
183. Haverkorn, M. J. 1993. Glycopeptide sensitivity of staphylococci. J. Infect. 27:335-338.
184. Hayden, M. K., G. I. Koenig, and G. M. Trenholme. 1994. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob. Agents Chemother. 38:1225-1229.
185. Hayden, M. K., G. M. Trenholme, J. E. Schultz, and D. F. Sahm. 1993. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J. Infect. Dis. 167:1224-1227.
186. Hayek, L. J. H. E. 1993. Erisipelothrix endocarditis affecting a porcine xenograft heart valve. J. Infect. 27:203-204.
187. Herman, D. J., and D. N. Gerding. 1991. Screening and treatment of infections caused by resistant enterococci. Antimicrob. Agents Chemother. 35:215-219.
188. Herwaldt, L., L. Boyken, and M. Pfaller. 1991. In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. Eur. J. Clin. Microbiol. Infect. Dis. 10: 1007-1012.
189. Herzstein, J., J. L. Ryan, R. J. Mangi, T. P. Greco, and V. T. Andriole. 1984. Optimal therapy for enterococcal endocarditis. Am. J. Med. 76:186-191.
190. Hindes, R. G., S. H. Willey, G. M. Eliopoulos, L. B. Rice, C. T. Eliopoulos, B. E. Murray, and R. C. Moellering, Jr. 1989. Treatment of experimental endocarditis caused by a β-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob. Agents Chemother. 33:1019-1022.
191. Hoban, D. J., B. Weshnoweski, L. Palatnick, C. G. Zhanel, and R. J. Davidson. 1992. In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. J. Antimicrob. Chemother. 30(Suppl. A):59-65.
192. Hospital Infection Control Practices Advisory Committee (HICPAC). 1995. Recommendations for preventing the spread of vancomycin resistance. Infect. Control Hosp. Epidemiol. 16:105-113.
193. Huband, M. D., M. A. Cohen, M. A. Meservey, G. E. Roland, S. L. Yoder, M. E. Dazer, and J. M. Domagala. 1993. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Antimicrob. Agents Chemother. 37:2563-2570.
194. Hunter, P. R., R. C. George, and J. W. Griffiths. 1990. Mathematical modeling of antimicrobial susceptibility data of Staphylococcus haemolyticus for 11 antimicrobial agents, including three experimental glycopeptides and an experimental lipoglycopeptide. Antimicrob. Agents Chemother. 34: 1769-1772.
195. Huygens, F. 1993. Vancomycin binding to cell walls of non-streptococcal vancomycin-resistant bacteria. J. Antimicrob. Chemother. 32:551-558.
196. Idika, N., S. F. Lawal, T. Odugbemi, and H. A. Cocker. 1991. Occurence of Leuconostoc mesenteroides and leuconostoc-like organism in Lagos, Nigeria. East Afr. Med. J. 68:969-974.
197. Ingerman, M., P. G. Pitsakis, A. Rosenberg, M. T. Hessen, E. Abrutyn, B. E. Murray, and M. E. Levison. 1987. β-Lactamase production in experimental endocarditis due to an aminoglycoside-resistant Streptococcus faecalis. J. Infect. Dis. 155:1226-1232.
198. Isenberg, H. D., E. M. Vellozzi, J. Shapiro, and L. G. Rubin. 1988. Clinical laboratory challenges in the recognition of Leuconostoc spp. J. Clin. Microbiol. 26:479-483.
199. Jansen, B., D. Stefanik, I. Hungenberg, and F. Schumacher-Perdreau. 1993. Evaluation of three methods (agar dilution, E test, agar disc diffusion) for susceptibility testing of staphylococci and enterococci against vancomycin and teicoplanin, abstr. 1019, p. 240. In Program and Abstracts of the 6th European Congress of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Disease.
200. Jean-Pierre, H., M. Riviere, H. Darbas, and G. Boyer. 1993. In vitro activity of glycopeptides on 114 coagulase-negative staphylococci: problems with the teicoplanin diffusion test, "alert" parameters indicating need for MIC determination. Pathol. Biol. 41:531-536.
201. Jensen, K. T., H. Schonheyder, A. Gottschau, and V. F. Thomsen. 1994. Impact of the agar medium and disc type on disc diffusion susceptibility testing against teicoplanin and vancomycin. Acta Pathol. Microbiol. Immunol. Scand. 102:94-102.
202. Jensen, K. T., H. Schonheyder, C. Pers, and V. F. Thomsen. 1992. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources. Acta Pathol. Microbiol. Immunol. Scand. 100:543-552.
203. Johnson, A. P., A. H. C. Uttley, N. Woodford, and R. C. George. 1990. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. 3:280-291.
204. Johnson, C. C., S. Taylor, P. Pitsakis, P. May, and M. E. Levison. 1992. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob. Agents Chemother. 36:2342-2345.
205. Jones, R. N. 1992. Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity. J. Antimicrob. Chemother. 29:725-726.
206. Jones, R. N., and A. L. Barry. 1989. In vitro evaluation of ramoplanin (A16686 or MDL62198): a new depsipeptide complex for potential topical use. Diagn. Microbiol. Infect. Dis. 12:279-282.
207. Jordens, J. Z., J. Bates, and D. T. Griffiths. 1994. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. 34:515-528.
208. Kaatz, G. W., and S. M. Seo. 1990. WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. Antimicrob. Agents Chemother. 34:1376-1380.
209. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1989. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 33:1184-1187.
210. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. Rybak. 1990. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 34:257-260.
211. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1991. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 35:1547-1550.
212. Kaatz, G. W., S. M. Seo, N. J. Dorman, and S. A. Lerner. 1990. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J. Infect. Dis. 162:103-108.
213. Kaatz, G. W., S. M. Seo, K. C. Lamp, E. M. Bailey, and M. J. Rybak. 1992. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 36:1192-1197.
214. Kahlmeter, G. 1992. Swedish Reference Group for Antibiotics concept for setting species specific interpretative breakpoints. Program of a workshop on new developments in disk diffusion susceptibility testing. In 5th European Congress on Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases.
215. Karanfil, L. V., M. Murphy, A. Josephson, R. Gaynes, L. Mandel, B. C. Hill, and J. M. Swenson. 1992. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect. Control Hosp. Epidemiol. 13:195-200.
216. Karchmer, A. W., G. L. Archer, and W. E. Dismukes. 1983. Staphylococcus epidermidis causing prosthetic valve endocarditis; microbiologic and clinical observations as guides to therapy. Ann. Intern. Med. 98:447-455.
217. Kenny, M. T., J. K. Dulworth, and M. A. Brackman. 1989. Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of teicoplanin MICs. J. Clin. Microbiol. 27:1409-1410.
218. Kenny, M. T., G. D. Mayer, J. K. Dulworth, M. A. Brackman, and K. Farrar. 1992. Evaluation of the teicoplanin broth microdilution and disk diffusion susceptibility tests and recommended interpretive criteria. Diagn. Microbiol. Infect. Dis. 15:609-612.
219. Khardori, N., M. Gandhi, J. Adame, L. Kalvakuntla, B. Rosenbaum, and G. P. Bodey. 1990. The activity in vitro of trospectomycin sulphate (U-63366F) against aminoglycoside-resistant enterococci. J. Antimicrob. Chemother. 25:777-785.
220. Klare, I., H. Heier, H. Claus, R. Reissbrodt, and W. Witte. 1995. vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol. Lett. 125:165-172.
221. Klare, I., H. Heier, H. Claus, and W. Witte. 1993. Environmental strains of Enterococcus faecium with inducible high-level resistance to glycopeptides. FEMS Microbiol. Lett. 106:23-30.
222. Klare, I., A. C. Rodloff, J. Wagner, W. Witte, and R. Hakenbeck. 1992. Overproduction of a penicillin-binding protein is not the only mechanism of penicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 36:783-787.
223. Kline, M. W., E. O. Mason, S. L. Kaplan, L. B. Lamberth, and G. S. Johnson. 1987. Comparative in vitro activity of LY 146032 and eight other antibiotics against gram-positive bacteria isolated from children. J. Antimicrob. Chemother. 20:203-207.
224. Knox, J. R., and R. F. Pratt. 1990. Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein. Antimicrob. Agents Chemother. 34:1342-1347.
225. Lamp, K. C., M. J. Rybak, E. M. Bailey, and G. W. Kaatz. 1992. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36:2709-2714.
226. Landman, D., N. K. Mobarakai, and J. M. Quale. 1993. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antimicrob. Agents Chemother. 37:1904-1908.
227. Lavoie, S. R., E. S. Wong, P. E. Coudron, D. S. Williams, and S. M. Markowitz. 1993. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a β-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis. Antimicrob. Agents Chemother. 37:1447-1451.
228. Lawrence, T., C. Rotstein, T. R. Beam, Jr., E. A. Gorzynski, and D. Amsterdam. 1993. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical isolates of grampositive cocci. Antimicrob. Agents Chemother. 37:896-900.
229. Leclercq, R., E. Bingen, Q. H. Su, N. Lambert-Zechovski, P. Courvalin, and J. Duval. 1991. Effects of combinations of β-lactams. daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob. Agents Chemother. 35:92-98.
230. Leclercq, R., E. Derlot, J. Duval, and P. Courvalin. 1988. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319:157-161.
231. Leclercq, R., E. Derlot, M. Weber, J. Duval, and P. Courvalin. 1989. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 33:10-15.
232. Leclercq, R., S. Dutka-Malen, J. Duval, and P. Courvalin. 1992. Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob. Agents Chemother. 36:2005-2008.
233. Lee, B. L., M. Sachdeva, and H. F. Chambers. 1991. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 35:2505-2508.
234. Lina, B., J. Troncy, A. Savey, and J. Fleurette. 1993. Septicimie a Enterococcus faecium resistant aux glycopeptides chez un patient aplastique. Med. Mal. Infect. 23:673-674.
235. Linden, P., A. W. Pasculle, S. Riddler, S. Kusne, A. Silverman, and J. Dean. 1994. Quinupristin-dalfopristin (RP 59500) for the treatment of serious infection due to high-level vancomycin-resistant Enterococcus faecium, abstr. M68. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
236. Livornese, L. L., Jr., S. Dias, C. Samel, B. Romanowski, S. Taylor, P. May, P. Pitsakis. G. Woods, D. Kaye, M. E. Levison, and C. C. Johnson. 1992. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann. Intern. Med. 117:112-116.
237. Livornese, L. L., M. Gold, C. C. Johnson, R. Measley, D. Kaye, O. Korzeniowski, M. L. Walsh, C. Samel, M. Hessen, and M. E. Levison. 1993. Clinical evaluation of teicoplanin in the treatment of gram-positive bacterial intravascular infections. J. Antimicrob. Chemother. 31:188-191.
238. Longfield, R. N., W. G. Wortham, L. L. Fletcher, and W. F. Nauscheutz. 1992. Clustered bacteremias in a haemodialysis unit: cross-contamination of blood tubing from ultrafiltrate waste. Infect. Control Hosp. Epidemiol. 13:160-164.
239. Lonzano, F., J. E. Corzo, C. Nogales, and F. Garcia-Bragado. 1992. Bacteremia due to vancomycin-resistant Enterococcus faecium of VanB phenotype during prophylaxis with vancomycin. Clin. Infect. Dis. 15:752-753.
240. Losonsky, G. A., A. Wolf, R. S. Schwalbe, J. Nataro, C. B. Gibson, and E. W. Lewis. 1994. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin. Infect. Dis. 19:163-165.
241. Louie, A., A. L. Baltch, W. J. Ritz, and R. P. Smith. 1991. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria. Chemotherapy (Basel) 37:275-282.
242. Lynn, W. A., E. Clutterbuck, S. Want, V. Markides, S. Lacey, T. R. Rogers, and J. Cohen. 1994. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 344: 1025-1026.
243. MacGowan, A. P., D. S. Reeves, C. Wright, and S. C. Glover. 1991. Tricuspid valve infective endocarditis and pulmonary sepsis due to Erysipelothrix rhusiopathiae successfully treated with high doses of ciprofloxacin but complicated by gynaecomastia. J. Infect. 22:100-101.
244. Mackey, T., V. Lejeune, M. Janssens, and G. Wauters. 1993. Identification of vancomycin-resistant lactic bacteria isolated from humans. J. Clin. Microbiol. 31:2499-2501.
245. Mainardi, J.-L., D. M. Shlaes, R. V. Goering, J. H. Shlaes, J. F. Acar, and F. W. Goldstein. 1995. Decreased teicoplanin-susceptibility of methicillin-resistant strains of Staphylococcus aureus. J. Infect. Dis. 171:1646-1650.
246. Mandell, G. L., E. Lindsey, and E. W. Hook. 1970. Synergism of vancomycin and streptomycin for enterococci. Am. J. Med. Sci. 259:346-349.
247. Manso, E., G. De Sio, F. Biavasco, P. E. Varaldo, G. Sambo, and C. Maffei. 1993. Vancomycin-resistant enterococci. Lancet 342:616-617.
248. Martin, E., M. Nouvellon, M. Pestel, and J. F. Lemeland. 1993. Teicoplanin susceptibility testing against coagulase-negative staphylococci: comparison of E test and agar dilution MICs, abstr. 257. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
249. Mastro, T. D., J. S. Spika, P. Lozano, J. Appel, and R. R. Facklam. 1990. Vancomycin-resistant Pediococcus acidilactici: nine cases of bacteremia. J. Infect. Dis. 161:956-960.
250. Maugein, J., P. Crouzit, P. Cony Makhoul, and J. Fourche. 1992. Characterization and antibiotic susceptibility of Pediococcus acidilactici strains isolated from neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 11: 383-385.
251. Maugein, J., J. L. Pellegrin, G. Brossard, J. Fourche, B. Leng, and J. Reiffers. 1990. In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob. Agents Chemother. 34:901-903.
252. Megran, D. W. 1992. Enterococcal endocarditis. Clin. Infect. Dis. 15:63-71.
253. Messer, J., and P. E. Reynolds. 1992. Modified peptidoglycan precursors produced by glycopeptide-resistant enterococci. FEMS Microbiol. Lett. 94:195-200.
254. Miniter, P. M., T. F. Patterson, M. A. Johnson, and V. T. Andriole. 1987. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob. Agents Chemother. 31:1199-1203.
255. Miranda, A. G., A. R. Wanger, K. V. Singh, and B. E. Murray. 1992. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob. Agents Chemother. 36:1325-1328.
256. Mobarakai, N., D. Landman, and J. M. Quale. 1994. In vitro activity of trospectomycin, a new aminocyclitol antibiotic, against multidrug-resistant Enterocaccus faecium. J. Antimicrob. Chemother. 33:319-321.
257. Mobarakai, N., J. M. Quale, and D. Landman. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387.
258. Moellering, R. C., Jr. 1991. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J. Antimicrob. Chemother. 28:1-12.
259. Moellering, R. C., Jr., B. E. Murray, S. C. Schoenbaum, J. Adler, and C. B. Wennersten. 1980. A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis. J. Infect. Dis. 141:81-86.
260. Moellering, R. C., Jr., and C. Wennersten. 1983. Therapeutic potential of rifampin in enterococcal infections. Rev. Infect. Dis. 5(Suppl. 3):S528-S532.
261. Montecalvo, M. A., H. Horowitz, C. Gedris, C. Carbonaro, F. C. Tenover, A. Issah, P. Cook, and G. P. Wormser. 1994. Outbreak of vancomycin-, ampicillin-. and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob. Agents Chemother. 38:1363-1367.
262. Moody, J. A., L. R. Peterson, and D. N. Gerding. 1985. In vitro activity of ciprofloxacin combined with azlocillin. Antimicrob. Agents Chemother. 28: 849-850.
263. Moroni, M. C., C. Granozzi, R. Lorenzetti, F. Parenti, M. Sosio, and M. Denaro. 1989. Cloning of a DNA region of Actinoplanes teichomyceticus conferring teicoplanin resistance. FEBS Lett. 253:108-112.
264. Morrison, D. Unpublished data.
265. Morrison, D., T. Alonso, J. Linares, and B. D. Cookson. 1992. The use of various typing schemes to explore the epidemiological aspects of vancomycin-resistant Enterococcus faecalis, abstr. 1166. In Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
266. Morrison, D., N. Woodford, V. Briant, J. Wade, M. Casewell, R. C. George, and B. D. Cookson. 1992. Enterococcus faecium resistant to vancomycin and gentamicin causing cross-infection on a liver unit, abstr. 1173. In Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
267. Morrison, D., N. Woodford, A. Johnson, R. George, and B. Cookson. 1994. Review of acquired vancomycin resistance in enterococci submitted to a reference laboratory during a five year period (1988-1993), abstr. F2/5, p. 19. In Program and Abstracts of the 3rd International Conference of the Hospital Infection Society (book 1). Hospital Infection Society. London.
268. Morrison, D., N. Woodford, M. Solaun, U. Riley, G. Bignardi, L. Goldberg, B. Cookson, and A. Johnson. 1994. The use of pulsed field gel electrophoresis and ribotyping to study the epidemiology of a cluster of multi-resistant Enterococcus faecium causing infections on a renal unit, abstr. PA31, p. 91. In Program and Abstracts of the 3rd International Meeting on Bacterial Epidemiological Markers.
269. Moulin, F., S. Dumontier, C. Loubeyre-Unique, P. Saulnier, and A. Andremont. 1994. Epidemiology of colonization and infection by vancomycin-resistant enterococci in hospitalized cancer patients, abstr. C-213. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.
270. Muranaka, K., and D. Greenwood. 1988. The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin. J. Antimicrob. Chemother. 21:545-554.
271. Murray, B. E. 1990. The life and times of the enterococcus. Clin. Microbiol. Rev. 3:46-65.
272. Murray, B. E., B. Mederski-Samoraj, S. K. Foster, J. L. Brunton, and P. Harford. 1986. In-vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin. J. Clin. Invest. 77:289-293.
273. Murray, B. E., K. V. Singh, S. M. Markowitz, H. A. Lopardo, J. E. Patterson, M. J. Zervos, E. Rubeglio, G. M. Eliopoulos, L. B. Rice, F. W. Goldstein, S. G. Jenkins, G. M. Caputo, R. Nasnas, L. S. Moore, E. S. Wong, and G. Weinstock. 1991. Evidence for clonal spread of a single strain of β-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J. Infect. Dis. 163:780-785.
274. Nachman, S. A., R. Verma, and M. Egnor. 1995. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microb. Drug Res. 1:95-96.
275. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved standard M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
276. National Committee for Clinical Laboratory Standards. 1990. Performance standards for antimicrobial disk susceptibility tests, 4th ed. Approved standard M2-A4. National Committee for Clinical Laboratory Standards. Villanova, Pa.
277. National Committee for Clinical Laboratory Standards. 1991. Performance standards for antimicrobial susceptibility testing; third informational supplement, M100-S3. National Committee for Clinical Laboratory Standards, Villanova. Pa.
278. National Committee for Clinical Laboratory Standards. 1992. Performance standards for antimicrobial susceptibility testing; fourth informational supplement, M100-S4. National Committee for Clinical Laboratory Standards, Villanova. Pa.
279. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
280. National Committee for Clinical Laboratory Standards. 1993. Performance standards for antimicrobial disk susceptibility tests, 5th ed. Approved standard M2-A5. National Committee for Clinical Laboratory Standards, Villanova. Pa.
281. Navarro, F., and P. Courvalin. 1994. Analysis of genes encoding D-alanine: D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens. Antimicrob. Agents Chemother. 38:1788-1793.
282. Neu, H. C. 1988. Glycopeptides and lipopeptides. Agents trying to meet the demands of the future. Antimicrob. Newsl. 5:77-84.
283. Neu, H. C., N. X. Chin, and W. W. Niu. 1992. In vitro activity of the new glycopeptide decaplanin. Eur. J. Clin. Microbiol. Infect. Dis. 11:458-462.
284. Ngui-Yen, J. H., E. A. Bryce, C. Porter, and J. A. Smith. 1992. Evaluation of the E test by using selected gram-positive bacteria. J. Clin. Microbiol. 30:2150-2152.
285. Nicas, T. I. 1995. Activity of novel semi-synthetic glycopeptides against vancomycin-resistant enterococci, abstr. 560, 107-108. In Program and Abstracts of the 7th European Congress on Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases.
286. Nicas, T. I., C. T. Cole, D. A. Preston, A. A. Schabel, and R. Nagarajan. 1989. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob. Agents Chemother. 33:1477-1481.
287. Nicas, T. I., C. Y. E. Wu, J. N. Hobbs, Jr., D. A. Preston, and N. E. Allen. 1989. Characterization of vancomycin resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 33:1121-1124.
288. Noble, W. C., Z. Virani, and R. G. A. Cree. 1992. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphyhcoccus aureus. FEMS Microbiol. Lett. 93:195-198.
289. Noskin, G. A., P. Mehl, and J. R. Warren. 1993. Bactericidal activity of fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 37:2470-2473.
290. Noskin, G. A., L. R. Peterson, and J. R. Warren. 1995. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin. Infect. Dis. 20:296-301.
291. O'Connell, B., P. V. Browne, M. T. Cafferkey, and S. R. McCann. 1993. Coagulase-negative staphylococcal bacteraemia treated with teicoplanin. J. Antimicrob. Chemother. 31:438-439.
292. O'Donovan, C. A., P. Fan-Havard, F. T. Tecson-Tumang, S. M. Smith, and R. H. K. Eng. 1994. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn. Microbiol. Infect. Dis. 18:105-109.
293. O'Hare, M. D., G. Ghosh, D. Felmingham, and R. N. Gruneberg. 1990. In-vitro studies with ramoplanin (MDL 62,198); a novel lipoglycopeptide antimicrobial. J. Antimicrob. Chemother. 25:217-220.
294. O'Hare, M. D., and P. E. Reynolds. 1992. Novel membrane proteins present in teieoplanin-resistant, vancomycin-sensitive, coagulase-negative Staphylococcus spp. J. Antimicrob. Chemother. 30:753-768.
295. Oppenheim, B. A., J. W. Hartley, W. Lee, and J. P. Burnie. 1989. Outbreak of coagulase-negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. Br. Med. J. 299:294-297.
296. Orr, K. E., F. K. Gould. J. D. Perry, M. Ford, S. Morgan, P. R. Sisson, and D. Morrison. 1994. Therapeutic beds: the Trojan horses of the 1990s? Lancet 344:65-66.
297. Ortega, L., J. Lite, and J. Garau. 1991. Bacteremia caused by vancomycin-resistant Enterococcus faecalis. Report of 2 cases. Enferm. Infec. Microbiol. Clin. 9:547-550.
298. Patterson, J. E., S. M. Colodny, and M. J. Zervos. 1988. Serious infection due to β-lactamase-producing Streptococcus faecalis with high-level resistance to gentamicin. J. Infect. Dis. 158:1144-1145.
299. Peetermans, W. E., F. W. Sebens, and H. F. L. Guiot. 1991. Vancomycin-resistant Enterococcus faecalis in a bone-marrow transplant recipient. Scand. J. Infect. Dis. 23:105-109.
300. Perri, M. B., J. W. Chow, and M. J. Zervos. 1993. In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci. Diagn. Microbiol. Infect. Dis. 17:151-155.
301. Peterson, L. R., J. A. Moody, C. E. Fasching, and D. N. Gerding. 1987. In vivo and in vitro activity of ciprofloxacin plus azlocillin against 12 streptococcal isolates in a neutropenic site model. Diagn. Microbiol. Infect. Dis. 7:127-136.
302. Piddock, L. J. V. 1994. New quinolones and gram-positive bacteria. Antimicrob. Agents Chemother. 38:163-169.
303. Pouedras, P., R. Leclercq, P. Y. Donnio, J. M. Sire, R. Mesnard, and J. L. Avril. 1992. Bacteremia due to vancomycin-resistant Enterococcus faecium of VanB phenotype during prophylaxis with vancomycin. Clin. Infect. Dis. 15:752-753.
304. Poulsen, P. N., S. H. Hartzen, and H. Rasmusen. 1989. In vitro activity of vancomycin against enterococci. Acta Pathol. Microbiol. Immunol. Scand. 97:897-900.
305. Qadri, S. M. H., Y. Ueno, H. Saldin, and B. A. Cunha. 1993. In vitro activity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin. Chemotherapy (Basel) 39:112-119.
306. Qadri, S. M. H., Y. Ueno, H. Saldin, D. D. Tullo, and G. C. Lee. 1993. Comparative antibacterial activity of the aminothiazolyl cephalosporin RU 29246. Chemotherapy (Basel) 39:175-181.
307. Quale, J. M., D. Landman, and N. Mobarakai. 1994. Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with ciprofloxacin and novobiocin. J. Antimicrob. Chemother. 34:797-802.
308. Quintiliani, R., Jr., and P. Courvalin. 1994. Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol. Lett. 119:359-364.
309. Quintiliani, R., Jr., S. Evers, and P. Courvalin. 1993. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J. Infect. Dis. 167:1220-1223.
310. Ramos, M. C., M. L. Grayson, G. M. Eliopoulos, and A. S. Bayer. 1992. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob. Agents Chemother. 36:1864-1869.
311. Rao, G. G., K. J. Morris, R. C. George, and N. Woodford. 1992. Vancomycin-resistant enterococci in a district general hospital. Lancet 340:1471-1472.
312. Reed, C., A. Efstratiou, D. Morrison, and N. Woodford. 1993. Glycopeptide-resistant Gemella haemolysans from blood. Lancet 342:927-928.
313. Reynolds, P. E., F. Depardieu, S. Dutka-Malen, M. Arthur, and P.
314. Reynolds, P. E., H. A. Snaith, A. J. Maguire, S. Dutka-Malen, and P. Courvalin. 1994. Analysis of peptidoglycan precursors in vancomycin resistant Enterococcus gallinarum BM4174. Biochem. J. 301:5-8.
315. Rhinehart, E., N. E. Smith, C. Wennersten, E. Gorss, J. Freeman, G. M. Eliopoulos, R. C. Moellering, Jr., and D. A. Golmann. 1990. Rapid dissemination of β-lactamase-producing. aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N. Engl. J. Med. 323:1814-1818.
316. Rice, L. B., C. T. Eliopoulos, J. D. C. Yao, G. M. Eliopoulos, and R. C. Moellering, Jr. 1992. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn. Microbiol. Infect. Dis. 15:173-176.
317. Riebel, W. J., and J. A. Washington. 1990. Clinical and microbiologic characteristics of pediococci. J. Clin. Microbiol. 28:1348-1355.
318. Rimailho, A., E. Lamp, B. Riou, C. Richard, E. Rottman, and P. Auzepy. 1988. Enterococcal bacteremia in a medical intensive care unit. Crit. Care Med. 16:126-129.
319. Rogers, T. R. (Hammersmith Hospital, London, England). 1994. Personal communication.
320. Rosato, A., J. Pierre, D. Billot-Klein, A. Buu-Hoi, and L. Gutmann. 1995. Inducible and constitutive expression of resistance to glycopeptides and vancomycin dependence in glycopeptide-resistant Enterococcus avium. Antimicrob. Agents Chemother. 39:830-833.
321. Rouse, M. S., R. M. Wilcox, N. K. Henry, J. M. Steckelberg, and W. R. Wilson. 1990. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 34:273-276.
322. Rubin, L. G., V. Tucci, E. Cercenado, G. Eliopoulos, and H. D. Isenberg. 1992. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect. Control Hosp. Epidemiol. 13:700-705.
323. Rybak, M. J., E. M. Bailey, K. C. Lamp, and G. W. Kaatz. 1992. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1109-1114.
324. Sader, H. S., M. A. Pfaller, F. C. Tenover, R. J. Hollis, and R. N. Jones. 1994. Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers. J. Clin. Microbiol. 32:2840-2842.
325. Sahm. D. F., L. Free, and S. Handwerger. 1995. Inducible and constitutive expression of vanC-1-encoded resistance to vancomycin in Enterococcus gallinarum. Antimicrob. Agents Chemother. 39:1480-1484.
326. Sahm, D. F., J. Kissinger, M. S. Gilmore, P. R. Murray, R. Mulder, J. Solliday, and B. Clarke. 1989. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 33:1588-1591.
327. Sahm, D. F., and G. T. Koburov. 1989. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob. Agents Chemother. 33:71-77.
328. Sahm, D. F., and L. Olsen. 1990. In vitro detection of enterococcal vancomycin resistance. Antimicrob. Agents Chemother. 34:1846-1848.
329. Saier, M. H., Jr. 1994. Bacterial sensor kinase/response regulator systems: an introduction. Res. Microbiol. 145:349-355.
330. Sanchez, M. L., M. S. Barrett, and R. N. Jones. 1992. The E-Test applied to susceptibility tests of gonococci, multiply-resistant enterococci, and Enterobacteriaceae producing potent β-lactamases. Diagn. Microbiol. Infect. Dis. 15:459-463.
331. Sanchez, M. L., R. P. Wenzel, and R. N. Jones. 1992. In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic. Antimicrob. Agents Chemother. 36:873-875.
332. Sanyal, D., and S. Bhandari. 1992. CAPD peritonitis caused by Lactobacillus rhamnosus. J. Hosp. Infect. 22:325-327.
333. Sanyal, D., and D. Greenwood. 1993. An electronmicroscope study of glycopeplide antibiotic-resistant strains of Staphylococcus epidermidis. J. Med. Microbiol. 39:204-210.
334. Sanyal, D., A. P. Johnson, R. C. George, B. D. Cookson, and A. J. Williams. 1991. Peritonitis due to vancomycin-resistant Staphytococcus epidermidis. Lancet 337:54.
335. Sanyal, D., A. P. Johnson, R. C. George, R. Edwards, and D. Greenwood. 1993. In-vitro characteristics of glycopeptide resistant strains of Staphylococcus epidermidis isolated from patients on CAPD. J. Antimicrob. Chemother. 32:267-278.
336. Sanyal, D., A. J. Williams, A. P. Johnson, and R. C. George. 1993. The emergence of vancomycin resistance in renal dialysis. J. Hosp. Infect. 24: 167-173.
337. Sapico, F. L., V. J. Ginunas, H. N. Canawati, and J. Z. Montgomerie. 1988. LY 146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model. Antimicrob. Agents Chemother. 32:81-83.
338. Sato, K., K. Hoshino, M. Tanaka, I. Hayakawa, and Y. Osada. 1992. Antimicrobial activity of DU-6859, a potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. 36:1491-1498.
339. Schaberg, D. R., W. I. Dillon, M. S. Terpenning, K. A. Robinson, S. F. Bradley, and C. A. Kauffman. 1992. Increasing resistance of enterococci to ciprofloxacin. Antimicrob. Agents Chemother. 36:2533-2535.
340. Scheid, W. M., and J. M. Keeley. 1983. Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis. J. Antimicrob. Chemother. 12(Suppl. D):65-78.
341. Schulz, J. E., and D. F. Sahm. 1993. Reliability of the E test for detection of ampicillin, vancomycin, and high-level aminoglycoside resistance in Enterococcus spp. J. Clin. Microbiol. 31:3336-3339.
342. Schuster, M. G., P. J. Brennan, and P. Edelstein. 1993. Persistent bacteremia with Erysipelothrix rhusiopathiae in a hospitalized patient. Clin. Infect. Dis. 17:783-784.
343. Schwalbe, R. S., J. T. Stapleton, and P. H. Gilligan. 1987 Emergence of vancomycin resistance in coagulase-negative staphylococci. N. Engl. J. Med. 316:927-931.
344. Seibert, G., D. Isert, N. Kiesel, M. Limbert, A. Markus, and E. Schrinner. 1992. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J. Antimicrob. Chemother. 29(Suppl. A):25-30.
345. Shlaes, D. M., A. Bouvet, C. Devine, J. H. Shlaes, S. al-Obeid, and R. Williamson. 1989. Inducible. transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob. Agents Chemother. 33:198-203.
346. Shlaes, D. M., L. Etter, and L. Gutmann. 1991. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob. Agents Chemother. 35:776-779.
347. Shlaes, D. M., J. H. Shlaes, S. Vincent, L. Etter, P. D. Fey, and R. V. Goering. 1993. Teicoplanin-resistant Staphylococcus aurcus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob. Agents Chemother. 37:2432-2437.
348. Shonekan, D., D. Mildvan, and S. Handwerger. 1992. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD 127,391 against blood isolates of gram-positive cocci. Antimicrob. Agents Chemother. 36:1570-1572.
349. Siebert, W. T., N. Moreland, and T. W. Williams, Jr. 1979. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistant Staphylococcus epidermidis. J. Infect. Dis. 139:452-457.
350. Simon, C., and M. Simon. 1991. In vitro activity of flomoxef and cefazolin in combination with vancomycin. Infection 19(Suppl. 5):S276-S278.
351. Sire, J. M., P. Y. Donnio, R. Mesnard, P. Pouedras, and J. L. Avril. 1992. Septicemia and hepatic abscess caused by Pediococcus acidilactici. Eur. J. Clin. Microbiol. Infect. Dis. 11:623-625.
352. Snell, J. J. S., D. F. J. Brown, S. F. Perry, and R. George. 1993. Antimicrobial susceptibility testing of enterococci: results of a survey conducted by the United Kingdom National External Quality Assessment Scheme for Microbiology. J. Antimicrob. Chemother. 32:401-411.
353. Soriano, F., J. Zapardiel, and R. Fernandez-Roblas. 1991. Comparative in vitro activity of the new glycopeptide SK&F 104662 against problematic gram-positive bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 10:782-784.
354. Sorrell, T. C., and P. J. Collignon. 1985. A prospective study of adverse reactions associated with vancomycin therapy. J. Antimicrob. Chemother. 16:235-241.
355. Sosio, M., R. Lorenzetti, F. Robbiati, and M. Denaro. 1991. Nucleotide sequence to a teicoplanin resistance gene from Actinoplanes teichomyceticus. Biochim. Biophys. Acta 1089:401-403.
356. Soussy, C. J., R. Cluzel, P. Courvalin, and the Comité de l'Antibiogramme de ta Société Française de Microbiologie. 1994. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. Eur. J. Clin. Microbiol. Infect. Dis. 13:238-246.
357. Spera, R. V., and B. F. Farber. 1992. Multiply resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA 268:2563-2564.
358. Sriskandan, S., S. Lacey, and L. Fischer. 1993. Isolation of vancomycin-resistant lactobacilli from three neutropenic patients with pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 12:649-650.
359. Stosor, V., W. Frauchiger, I. Cooper, L. Peterson, and G. Noskin. 1994. Survival of enterococci on environmental surfaces, abstr. L-42. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.
360. Stratton, C. W., and L. S. Weeks. 1990. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Diagn. Microbiol. Infect. Dis. 13:245-252.
361. Sullam, P. M., M. G. Tauber, C. J. Hackbarth, and M. A. Sande. 1985. Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 27:135-136.
362. Sussman, J. I., E. J. Baron, S. M. Goldberg, M. H. Kaplan, and R. A. Pizzarello. 1986. Clinical manifestations and therapy of lactobacillus endocarditis: report of a case and review of the literature. Rev. Infect. Dis. 8: 771-776.
363. Swenson, J. M., N. C. Clark, M. J. Ferraro, D. F. Sahm, G. Doern, M. A. Pfaller, L. B. Reller, M. P. Weinstein, R. J. Zabransky, and F. C. Tenover. 1994. Development of a standardized screening method for detection of vancomycin-resistant enterococci. J. Clin. Microbiol. 32:1700-1704.
364. Swenson, J. M., R. R. Facklam, and C. Thornsberry. 1990. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob. Agents Chemother. 34:543-549.
365. Swenson, J. M., M. J. Ferraro, D. F. Sahm, P. Charache, The National Committee for Clinical Laboratory Standards Working Group on Enterococci, and F. C. Tenover. 1992. New vancomycin disk diffusion breakpoints for enterococci. J. Clin. Microbiol. 30:2525-2528.
366. Tankovic, J., R. Leclercq, and J. Duval. 1993. Antimicrobial susceptibility of Pediococcus spp. and genetic basis of macrolide resistance in Pediococcus acidilactici HM 3020. Antimicrob. Agents Chemother. 37:789-792.
367. Tebas, P., R. Martinez Ruiz, F. Roman, P. Mendaza, J. C. Rodriguez Diaz, R. Daza, and J. M. L. de Letona. 1991. Early resistance to rifampicin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J. Infect. Dis. 163:204-205.
368. Tenenbaum, M. J., and J. F. Warner. 1975. Lactohacillus casei endocarditis. Ann. Intern. Med. 82:539.
369. Tenover, F. C., J. Tokars, J. Swenson, S. Paul, K. Spitalny, and W. Jarvis. 1993. Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. J. Clin. Microbiol. 31:1695-1699.
370. Thai, L. A., J. Vazquez, M. B. Perri, A. Beckley, S. Donabedian, G. W. Kaatz, J. E. Patterson, and M. J. Zervos. 1993. Activity of ampicillin plus sulbactam against β-lactamase producing enterococci in experimental endocarditis. J. Antimicrob. Chemother. 31:182-185.
371. Thauvin, C., G. M. Eliopoulos, S. Willey, C. Wennersten, and R. C. Moellering, Jr. 1987. Continuous infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob. Agents Chemother. 31:139-143.
372. Tikusis, L., and Z. A. Quraishi. 1993. Epidemiology of vancomycin-resistant enterococcus (VRE) in an intensive care unit. The role of handwashing feedback to control VRE. Am. J. Infect. Control 21:87.
373. Tofte, R. W., J. Solliday, and K. B. Crossley. 1984. Susceptibilities of enterococci to twelve antibiotics. Antimicrob. Agents Chemother. 25:532-533.
374. Torres, C., J. A. Reguera, M. J. Sanmartin, J. C. Perez-Diaz, and F. Baquero. 1994. vanA-mediated vancomycin-resistant Enterococcus spp. in sewage. J. Antimicrob. Chemother. 33:553-561.
375. Torres, C., C. Tenorio, M. Lantero, M. J. Gastanares, and F. Baquero. 1993. High-level penicillin resistance and penicillin-gentamicin synergy in Enterococcus faecium. Antimicrob. Agents Chemother. 37:2427-2431.
376. Townshend, R. H., A. E. Jephcott, and M. H. Yekta. 1973. Erysipelothrix septicaemia without endocarditis. Br. Med. J. i:464.
377. Traub, W. H., B. Leonhard, and D. Bauer. 1993. Enterococcus faecium: in vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains. Chemotherapy (Basel) 39:254-264.
378. Troke, M. S., K. R. Damerau, J. F. John, and R. W. Johnson. 1994. Application of a vanA probe to investigate a nosocomial cluster of vancomycin-resislant Enterococcus faecium. abstr. L-14. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology. Washington, D.C.
379. Truant, A. L., and V. Satishchandran. 1993. Comparison of the Streptex versus PathoDx for group D typing of vancomycin-resistant Enterococcus. Diagn. Microbiol. Infect. Dis. 16:89-91.
380. Tuazon, C. U., and H. Miller. 1983. Clinical and microbiologic aspects of serious infections caused by Staphylococcus epidermidis. Scand. J. Infect. Dis. 15:347-360.
381. Unal, S., J. Flokowitsch, D. L. Mullen, D. A. Preston, and T. I. Nicas. 1993. In-vitro synergy and mechanism of interaction between vancomycin and ciprofloxacin against enterococcal isolates. J. Antimicrob. Chemother. 31: 711-723.
382. Urkijo, J. C., M. Montejo, M. F. Mendoza, K. Aguirrebengoa, J. L. Hernandez, and C. Aguirre. 1992. Endocarditis por Lactobacillus. Enferm. Infec. Microbiol. Clin. 10:32-33.
383. Uttley, A. H. C., C. H. Collins, J. Naidoo, and R. C. George. 1988. Vancomycin-resistant enterococci. Lancet i:57-58.
384. Uttley, A. H. C., R. C. George, J. Naidoo, N. Woodford, A. P. Johnson, C. H. Collins, D. Morrison, A. J. Gilfillan, L. E. Fitch, and J. Heptonstall. 1989. High-level vancomycin-resistant enterococci causing hospital infection. Epidemiol. Infect. 103:173-181.
385. van Rensburg, C. E. J., and A. van Straten. 1994. An in-vitro investigation of the susceptibility of Enterococcus faecalis to clofazimine and B669. J. Antimicrob. Chemother. 33:356-358.
386. Vazquez, J., M. B. Perri, L. A. Thal, S. A. Donadedian, and M. J. Zervos. 1993. Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits. J. Antimicrob. Chemother. 32:715-721.
387. Veach, L. A., M. A. Pfaller, M. Barrett, F. P. Koontz, and R. P. Wenzel. 1990. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J. Clin. Microbiol. 28:2064-2068.
388. Vedel, G., M. Leruez, F. Lemann. E. Hraoui, and D. Ratovahery. 1990. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. Eur. J. Clin. Microbiol. Infect. Dis. 9:820-822.
389. Venditti, M., F. Biavasco, P. E. Varaldo, A. Macchiarelli, L. De Biase, B. Marino, and P. Serra. 1993. Catheter-related endocarditis due to glycopeptide-resistant Enterococcus faecalis in a transplanted heart. Clin. Infect. Dis. 17:524-525.
390. Venditti, M., V. Gelfusa, F. Castelli, C. Brandimarte, and P. Serra. 1990. Erysipelothrix rhusiopathiae endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 1:50-52.
391. Venditti, M., V. Gelfusa, A. Tarasi, C. Brandimarte, and P. Serra. 1990. Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae. Antimicrob. Agents Chemother. 34:2038-2040.
392. Venditti, M., A. Tarasi, P. Biaocchi, V. Lamonaca, and G. P. Testore. 1993. The activity 'in vitro' of trospectomycin against high-level antibiotic-resistant enterococci. Int. J. Antimicrob. Agents 3:123-127.
393. Venuti, E., J. Dean, and H. Fraimow. 1994. Characterization of vancomycin-resistant enterococci by polymerase chain reaction for vanB1 and vanB2, abstr. C-212. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.
394. Venuti, E., P. French, and H. Fraimow. 1992. In vitro activity of novobiocin alone and in combination with fluoroquinolones against high-level penicillin-resistant, vancomycin-resistant Enterococcus faecium, abstr. 250. In Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
395. Verbist, L., and J. Verhaegen. 1992. Comparative in-vitro activity of RP 59500. J. Antimicrob. Chemother. 30(Suppl. A):39-44.
396. Vincent, S., P. Minkler, B. Bincziewski, L. Etter, and D. M. Shlaes. 1992. Vancomycin resistance in Enterococcus gallinarum. Antimicrob. Agents Chemother. 36:1392-1399.
397. Wade, J. (King's College School of Medicine & Dentistry, London). 1994. Personal communication.
398. Wade, J., L. Baillie, N. Rolando, and M. Casewell. 1992. Pristinamycin for Enterococcus faecium resistant to vancomycin and gentamicin. Lancet 339: 312-313.
399. Wade, J. J., N. Desai, and M. W. Casewell. 1991. Hygienic hand disinfection for the removal of epidemic vancomycin-resistant Enterococcus faecium and gentamicin-resistant Enterobacter cloacae. J. Hosp. Infect. 18:211-218.
400. Wakebe, H., and S. Mitsuhashi. 1992. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob. Agents Chemother. 36:2185-2191.
401. Watanakunakorn, C. 1991. In vitro activity of trospectomycin against enterococci isolated from blood or other clinical materials. J. Antimicrob. Chemother. 27:873-875.
402. Watanakunakorn, C. 1993. Increasing prevalence of resistance to ampicillin, penicillin and vancomycin of enterococci isolated from blood cultures ring 1990-1991. J. Antimicrob. Chemother. 31:325-326.
403. Weckbach, L. S., and J. L. Staneck. 1993. Determination of teicoplanin MICs, using E test, abstr. 256. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
404. Whitman, M. S., P. G. Pitsakis, A. Zausner, L. L. Livornese, A. J. Osborne, C. C. Johnson, and M. E. Levison. 1993. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 37:2069-2073.
405. Wilhelm, M. P. 1991. Vancomycin. Mayo Clin. Proc. 66:1165-1170.
406. Willey, B. M., B. N. Kreiswirth, B. Eisner, and D. E. Low. 1993. Hybridization of enterococcal species to vanA may no longer be predictive of teicoplanin resistance, abstr. 119. In Program and Abstracts of the 33rd Interscienee Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
407. Willey, B. M., B. N. Kreiswirth, A. E. Simor, Y. Faur, M. Patel, G. Williams, and D. E. Low. 1993. Identification and characterization of multiple species of vancomycin-resistant enterococci, including an evaluation of Vitek software version 7.1. J. Clin. Microbiol. 31:2777-2779.
408. Willey, B. M., B. N. Kreiswirth, A. E. Simor, G. Williams, S. R. Scriver, A. Phillips, and D. E. Low. 1992. Detection of vancomycin resistance in Enterococcus species. J. Clin. Microbiol. 30:1621-1624.
409. Williamson, R., S. al-Obeid, J. H. Shlaes, F. W. Goldstein, and D. M. Shlaes. 1989. Inducible resistance to vancomycin in Enterococcus faecium D366. J. Infect. Dis. 159:1095-1104.
410. Williamson, R., S. B. Calderwood, R. C. Moellering, Jr., and A. Tomasz. 1983. Studies on the mechanism of intrinsic resistance to β-lactam antibiotics in group D streptococci. J. Gen. Microbiol. 129:813-822.
411. Wilson, A. P., D. Felmingham, M. Robbins, and R. Chopra. 1991. Enterococcus faecium sensitive to teicoplanin but not vancomycin. J. Hosp. Infect. 18:322-324.
412. Wilson, A. P. R., R. N. Gruneberg, and H. Neu. 1993. Dosage recommendations for teicoplanin. J. Antimicrob. Chemother. 32:792-796.
413. Woodford, N., A. P. Johnson, and R. C. George. 1991. Detection of glycopeptide resistance in clinical isolates of gram-positive bacteria. J. Antimicrob. Chemother. 28:483-486.
414. Woodford, N., A. P. Johnson, D. Morrison, A. T. Chin, and J. R. Stephenson. 1990. Two distinct forms of vancomycin resistance amongst enterococci. Lancet 335:226.
415. Woodford, N., A. P. Johnson, D. Morrison, J. G. M. Hastings, T. S. J. Elliott, A. Worthington, J. R. Stephenson, A. T. Chin, and J. L. Tolley. 1994. Vancomycin-dependent enterococci in the United Kingdom. J. Antimicrob. Chemother. 33:1066.
416. Woodford, N., B. L. Jones. Z. Baccus, H. A. Ludlam, and D. F. J. Brown. 1995. Linkage of vancomycin and high-level gentamicin resistance genes on the same plasmid in a clinical isolate of Enterococcus faecalis. J. Antimicrob. emother. 35:179-184.
417. Woodford, N., D. Morrison, A. P. Johnson, A. Bateman, J. G. M. Hastings, T. S. J. Elliott. and B. Cookson. Plasmid-mediated ranB glycopeptide resistance in enterococci. Submitted for publication.
418. Woodford, N., D. Morrison, A. P. Johnson, V. Briant, R. C. George, and B, Cookson. 1993. Application of DNA probes for rRNA and vanA genes to investigation of a nosocomial cluster of vancomycin-resistant enterococci. J. Clin. Microbiol. 31:653-658.
419. Woodford, N., D. Morrison, A. P. Johnson, and R. C. George. 1993. Antimicrobial resistance amongst enterococci isolated in the United Kingdom: a reference laboratory perspective. J. Antimicrob. Chemother. 32:344-346.
420. Woodford, N., D. Morrison, A. Johnson, W. Liu, N. Richards, T. Elliott, and J. Hastings. 1993. Transfer of an unusual vancomycin resistance determinant between Entenrococcus faecium on a renal unit, abstr. 120. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
421. Working Party of the British Society for Antimicrobial Chemotherapy. 1985. Antibiotic treatment of streptococcal and staphylococcal endocarditis. Lancet 11:815-817.
422. Working Party of the British Society for Antimicrobial Chemotherapy. 1991. A guide to sensitivity testing. J. Antimicrob. Chemother. 27(Suppl. D): 1-50.
423. Wright, G. D., T. R. Holman, and C. T. Walsh. 1993. Purification and characterization of VanR and the cytosolic domain of VanS: a two-component regulatory system required for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 32:5057-5063.
424. Wright. G. D., C. Molinas, M. Arthur, P. Courvalin, and C. T. Walsh. 1992. Characterization of VanY, a DD-carboxypeptidase from vancomycin-resistant Enterococcus faecium BM4147. Antimicrob. Agents Chemother. 36: 1514-1518.
425. Yamane, N., and R. N. Jones. 1994. In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin. Diagn. Microbiol. Infect. Dis. 14:337-345.
426. Yao, J. D. C., C. Thauvin-Eliopoulos, G. M. Eliopoulos, and R. C. Moellering, Jr. 1990. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a β-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob. Agents Chemother. 34:827-830.
427. Young, H. K. 1994. Do nonclinical uses of antibiotics make a difference? Infect. Control Hosp. Epidemiol. 15:484-487.
428. Zabransky, R. J., A. R. DiNuzzo, M. B. Huber, and G. L. Woods. 1994. Detection of vancomycin resistance in enterococci by the Vitek AMS system. Diagn. Microbiol. Infect. Dis. 20:113-116.
429. Zarlenga, L. J., M. S. Gilmore, and D. F. Sahm. 1992. Effects of amino acids on expression of enterococcal vancomycin resistance. Antimicrob. Agents Chemother. 36:902-905.